Based on the earnings transcript, Johnson & Johnson reported strong financial results for 2012, with notable growth in pharmaceuticals and medical devices and diagnostics. The company also highlighted its commitment to innovation, strategic growth, and a focus on emerging markets. The stock is likely to face short-term pressure due to the uncertainty around healthcare reform and the potential impact of generic competition. However, the company's long-term growth prospects and commitment to innovation suggest a positive outlook for the stock over the next 1-2 weeks.